VJHemOnc Podcast cover image

CLL therapy: the latest trial updates and innovative novel therapies for the future

VJHemOnc Podcast

00:00

Novel Treatments for CLL Patients Who Have Failed Prior Therapies

This chapter explores the phase 1 results of JCAR17, a CD19 targeted autologous CAR T-cell product, as a potential treatment for CLL patients who have failed previous therapies. It highlights the manageable side effects, high overall response rate, and achievement of undetectable minimal residual disease.

Transcript
Play full episode

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app